ARTBIO is a clinical-stage radiopharmaceutical biotechnology business that is working to create a new class of alpha radioligand medicines.
ARTBIO has raised $132.0M in total funding. The most recent round was Series B. The last funding was announced in July 2025.
ARTBIO's investors include B Capital, Omega Funds, Third Rock Ventures, Sofinnova Investments, F-Prime.
ARTBIO is headquartered in Cambridge, United States.
ARTBIO is a clinical-stage radiopharmaceutical biotechnology business that is working to create a new class of alpha radioligand medicines.
ARTBIO is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"ARTBIO — Funding & Investors." VCBacked, July 29, 2025, https://www.vcbacked.co/company/artbio. Accessed July 22, 2026.
VCBacked. (2025). ARTBIO — Funding & Investors. Retrieved July 22, 2026, from https://www.vcbacked.co/company/artbio
{{cite web |title=ARTBIO — Funding & Investors |url=https://www.vcbacked.co/company/artbio |website=VCBacked |access-date=July 22, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated